Roche Holding AG RO.SW
Composite 57/100; the shares have moved about 24% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Income ranks 40/100 — a slight mark against it.
Quality ranks 75/100 — a strong point in its favour. Momentum ranks 66/100 — a moderate point in its favour. Growth ranks 59/100 — a slight point in its favour.
Income ranks 40/100 — a slight mark against it. Valuation ranks 41/100 — a slight mark against it. Balance-sheet strength ranks 48/100 — a slight mark against it.
What the company does Roche Holding AG (RO.SW) is a Swiss healthcare giant focused on pharmaceuticals (oncology, immunology, infectious diseases) and diagnostics (cancer, diabetes, COVID-19). It operates globally and recently partnered with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors.
Key financials Roche reports ROE 38.1%, ROA 13.5%, gross/operating/net margins 74.2%/36.2%/19.6%, and revenue/EPS growth of -1.2%/-7.7%. Debt/equity is 0.91, net debt/EBITDA 0.98, and dividend yield 2.6% with a 63.9% payout ratio.
Stock health Momentum is strong: +36.86% over 12 months, +13.15% in 3 months, and RSI(14) at 72.50. Strength and momentum pillar scores are 49.6 and 68.0, respectively, while valuation is 40.7/100.
Price vs fair value The stock trades at a **PREMIUM of 24.50%** to our fair-value estimate and a **PREMIUM of 1.24%** to the analyst 12-month target. - Recent FDA/EU approvals for key treatments (Simply Wall St.) - Positive momentum amid broader sector strength (momentum metrics) - Premium valuation reflected in high P/E 24.31 and P/B 8.90 - Analyst target implies limited upside from current levels
Looking forward Forward P/E is 17.89 and PEG is 0.50, suggesting reasonable growth expectations. Pipeline progress and regulatory wins support long-term stability, but valuation remains rich relative to fair value.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.